Data support Qiagen's A/H1N1 diagnostic

5 May 2009

Analyses performed by the German Bernhard Nocht Institute for Tropical Medicine have proven that the influenza A/H1N1 virus can be  unequivocally detected using a screening test developed by Dutch  diagnostics firm Qiagen.

The company's artus Influenza LC RT PCR Kit was successfully used to  screen a female patient who had come down with the disease in Mexico and  is currently being treated at the Eppendorf University Hospital in  Hamburg, Germany.

According to Qiagen, the artus kit is considered to be one of the most  widely used assays in influenza screening and serves as standard for the  detection of influenza A viruses in numerous laboratories around the  world. The test was also used by the Instituto de Salud Carlos III,  Centro Nacional de Microbiologia in Majadahonda, Spain, to screen for  influenza A infections. The institute verified several possible  infections with the H1N1 strain that occurred during the last few days  and the kit has consequently been used by other hospitals in Spain.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight